TY - JOUR
T1 - Epidemiological profile of multidrug-resistant and extensively drug-resistant Mycobacterium Tubrculosis among Congolese patients
AU - Elion Assiana, Darrel Ornelle
AU - Abdul, Jabar Babatunde Pacôme Achimi
AU - Linguissi, Laure Stella Ghoma
AU - Epola, Micheska
AU - Vouvoungui, Jeannhey Christevy
AU - Mabiala, Albert
AU - Biyogho, Christopher Mebiame
AU - Ronald Edoa, Jean
AU - Adegbite, Bayodé Roméo
AU - Adegnika, Ayola Akim
AU - Elton, Linzy
AU - Canseco, Julio Ortiz
AU - McHugh, Timothy D.
AU - Ahombo, Gabriel
AU - Ntoumi, Francine
N1 - Funding Information: We are grateful to the children and adults who consented to participate in this study. We thank the staff of the Makélékélé Hospital for their participation. We also thank the staff of TB Lab CERMEL. FN and AAA are a member of CANTAM (EDCTPRegNet2015-1045), this work has been supported through the Central Africa Network on Tuberculosis, HIV/AIDS and Malaria (CANTAM), which is a network of excellence supported by The European & Developing Countries Clinical Trials Partnership (EDCTP). Funding Information: This study received financial support from CANTAM (EDCTP-RegNet2015-1045). Publisher Copyright: © 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Background: There is paucity of data on the prevalence and distribution of multidrug- Resistant-Tuberculosis (MDR-TB) in the Republic of Congo. Among the challenges resides the implementation of a robust TB resistance diagnostic program using molecular tools. In resource limited settings there is a need to gather data to enable prioritization of actions. The objective of this study was is to implement molecular tools as a best of diagnosing MDR and XDR-TB among presumptive tuberculosis patients referred to reference hospital of Makelekele in Brazzaville, Republic of the Congo. Methods: We have conducted a cross-sectional study, including a total of 92 presumptive pulmonary tuberculosis patients and who had never received treatment recruited at the reference hospital of Makelekele from October 2018 to October 2019. The socio-demographic and clinical data were collected as well as sputum samples. Rifampicin resistance was investigated using Xpert (Cepheid) and second-line TB drugs Susceptibility testing were performed by the Brucker HAIN Line Probe Assay (GenoType MTBDRsl VER 2.0 assay) method. Results: From the 92 recruited patients, 57 (62%) were found positive for the Mycobacterium tuberculosis complex. The prevalence of rifampicin-resistant tuberculosis (RR-TB) was 9.8% (9/92) and importantly 2.2% were pre-XDR/XDR. Conclusion: This study showed a high rate of rifampicin resistance and the presence of extensively drug-resistant tuberculosis in the study area in new patients. This study highlights the need for further studies of TB drug resistance in the country.
AB - Background: There is paucity of data on the prevalence and distribution of multidrug- Resistant-Tuberculosis (MDR-TB) in the Republic of Congo. Among the challenges resides the implementation of a robust TB resistance diagnostic program using molecular tools. In resource limited settings there is a need to gather data to enable prioritization of actions. The objective of this study was is to implement molecular tools as a best of diagnosing MDR and XDR-TB among presumptive tuberculosis patients referred to reference hospital of Makelekele in Brazzaville, Republic of the Congo. Methods: We have conducted a cross-sectional study, including a total of 92 presumptive pulmonary tuberculosis patients and who had never received treatment recruited at the reference hospital of Makelekele from October 2018 to October 2019. The socio-demographic and clinical data were collected as well as sputum samples. Rifampicin resistance was investigated using Xpert (Cepheid) and second-line TB drugs Susceptibility testing were performed by the Brucker HAIN Line Probe Assay (GenoType MTBDRsl VER 2.0 assay) method. Results: From the 92 recruited patients, 57 (62%) were found positive for the Mycobacterium tuberculosis complex. The prevalence of rifampicin-resistant tuberculosis (RR-TB) was 9.8% (9/92) and importantly 2.2% were pre-XDR/XDR. Conclusion: This study showed a high rate of rifampicin resistance and the presence of extensively drug-resistant tuberculosis in the study area in new patients. This study highlights the need for further studies of TB drug resistance in the country.
KW - Epidemiological profile
KW - Extensively drug-resistant TB
KW - Line Probe Assay SL
KW - Multidrug-resistant TB
KW - Republic of Congo
KW - Xpert MTB / RIF
UR - http://www.scopus.com/inward/record.url?scp=85121467050&partnerID=8YFLogxK
U2 - https://doi.org/10.1186/s12941-021-00488-x
DO - https://doi.org/10.1186/s12941-021-00488-x
M3 - Article
C2 - 34920727
SN - 1476-0711
VL - 20
SP - 84
JO - Annals of clinical microbiology and antimicrobials
JF - Annals of clinical microbiology and antimicrobials
IS - 1
M1 - 84
ER -